≡

Active Biglycan (BGN)

DSPG1; PG-S1; PGI; SLRR1A; Biglycan Proteoglycan; Bone/cartilage proteoglycan I

ACTIVITY TEST

Biglycan, also known as BGN, is a a small leucine-rich repeat proteoglycan (SLRP). It can be detected in a variety of extracellular matrix tissues, including bone, cartilage and tendon. Biglycan consists of a protein core containing leucine-rich repeat regions and two glycosaminoglycan (GAG) chains consisting of either chondroitin sulfate (CS) or dermatan sulfate (DS). Non-glycanated forms of biglycan (no GAG chains) increase with age in human articular cartilage. Biglycan interacts with collagen, both via the core protein and GAG chains. Biglycan plays a role in the mineralisation of bone. Biglycan core protein binds to the growth factors BMP-4 and influences its bioactivity. To test the effect of BGN on cell apoptosis, 3T3-L1 cells were seeded into triplicate wells of 96-well plates and allowed to attach overnight, then the medium was replaced with various concentrations of recombinant human BGN. After incubated for 72h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10 µl of CCK-8 solution was added to each well of the plate, then the absorbance at 450 nm was measured using a microplate reader after incubating the plate for 1h at 37℃. Proliferation of 3T3-L1 cells after incubation with BGN for 72h observed by inverted microscope was shown in Figure 1. Cell viability was assessed by CCK-8 (Cell Counting Kit-8 ) assay after incubation with recombinant human BGN for 72h. The result was shown in Figure 2. It was obvious that BGN significantly inhibit cell viability of 3T3-L1 cells. The ED50 is 0.89 μg/mL.

USAGE

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Sci Rep.  Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysreCavia (Guinea pig )lation of biglycan Pubmed:27295191
Cell Death & Disease Tenomodulin is essential for prevention of adipocyte accumulation and fibrovascular scar formation during early tendon healing. pubmed:29022912
Diabetes & Vascular Disease Research Degenerative aortic valve disease and diabetes: Implications for a link between proteoglycans and diabetic disorders in the aortic valve Pubmed: 30563371
博士论文 Die Rolle der extrazellulären Matrix in der degenerativen Aortenklappenerkrankung unter dem Einfluss von Diabetes
J Transl Med Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans 33407555
researchsquare Inhibition of Stromal Biglycan Promotes Normalization of the Tumor Microenvironment and Enhances Chemotherapeutic Efficacy 33966638
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPJ226Hu01 Recombinant Biglycan (BGN) Positive Control; Immunogen; SDS-PAGE; WB.
APJ226Hu03 Active Biglycan (BGN) Cell culture; Activity Assays.
RPJ226Hu03 Recombinant Biglycan (BGN) Positive Control; Immunogen; SDS-PAGE; WB.
RPJ226Hu02 Recombinant Biglycan (BGN) Positive Control; Immunogen; SDS-PAGE; WB.
PAJ226Hu01 Polyclonal Antibody to Biglycan (BGN) WB; IHC; ICC; IP.
PAJ226Hu02 Polyclonal Antibody to Biglycan (BGN) WB; IHC; ICC; IP.
LAJ226Hu71 Biotin-Linked Polyclonal Antibody to Biglycan (BGN) WB; IHC; ICC.
SEJ226Hu ELISA Kit for Biglycan (BGN) Enzyme-linked immunosorbent assay for Antigen Detection.
LMJ226Hu Multiplex Assay Kit for Biglycan (BGN) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.